Published • loading... • Updated
GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports
The deal would expand GE HealthCare’s pharmaceutical diagnostics unit and add radioactive chemicals used in cancer scans, the report said.
- On Sunday, the Financial Times reported that GE HealthCare Technologies is in talks to acquire radiopharmaceutical developer Sofie Biosciences for $1 billion, citing people familiar with the matter.
- Based in Dulles, Virginia, the 20-year-old Sofie develops radioisotopes for PET scans to detect pancreatic and gastro-oesophageal cancers.
- Acquiring Sofie would bolster GE HealthCare's pharmaceutical diagnostics division, marking the company's second major acquisition since General Electric's 2024 three-way split.
- An announcement could come as soon as next week, though neither GE HealthCare nor Sofie has commented on the reported negotiations.
- GE HealthCare is performing "a comprehensive strategic review" of its Patient Care Solutions business to "create a more focused and connected end-to-end imaging ecosystem.
Insights by Ground AI
12 Articles
12 Articles
GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports
GE HealthCare Technologies is in talks over a possible $1 billion deal to buy radiopharmaceutical developer Sofie Biosciences, the Financial Times reported on Sunday, citing people familiar with the matter.
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources12
Leaning Left0Leaning Right4Center7Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
C 64%
R 36%
Factuality
To view factuality data please Upgrade to Premium
